Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

WGBS of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

ABSTRACT: WGBS of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

PROVIDER: PRJNA835121 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19090500_1.fastq.gz	Fastqsanger.gz
	SRR19090500_2.fastq.gz	Fastqsanger.gz
	SRR19090501_1.fastq.gz	Fastqsanger.gz
	SRR19090501_2.fastq.gz	Fastqsanger.gz
	SRR19090502_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 124

Similar Datasets

WGBS of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

Project description:WGBS was generated for a cohort of ovarian cancer patients to identify DNA methylation changes between primary and recurrent ovarian cancer tumors from patients with and without BRCA1/2 mutations

2022-07-31 | GSE202245 | GEO

RNAseq of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

Project description:RNAseq was generated for a cohort of ovarian cancer patients to identify gene expression changes between primary and recurrent ovarian cancer tumors from patients with and without BRCA1/2 mutations

2023-08-19 | GSE240829 | GEO

RNAseq of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

Project description:RNAseq of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

| PRJNA1005317 | ENA

CGH profiles of BRCA1-mutated tumors

Project description:While new defects in BRCA1 are still being found, it is unclear whether current breast cancer diagnostics misses many BRCA1-associated cases. A reliable test that is able to indicate the involvement of BRCA1 deficiency in cancer genesis could support decision making in genetic counselling and clinical management. To find BRCA1-specific markers and explore the effectiveness of the current diagnostic strategy, we designed a classification method, validated it and examined whether we could find BRCA1-like breast tumours in a group of patients initially diagnosed as non-BRCA1/2 mutation carriers. A classifier was built based on array-CGH profiles of 18 BRCA1-related and 32 control breast tumours, and validated on independent sets of 16 BRCA1-related and 16 control breast carcinomas. Subsequently, we applied the classifier to 48 breast tumours of patients from Hereditary Breast and Ovarian Cancer (HBOC) families in whom no germ line BRCA1/BRCA2 mutations were identified. The classifier showed an accuracy of 91% when applied to the validation sets. In 48 non-BRCA1/2 patients, only two breast tumours presented a BRCA1-like CGH profile. Additional evidence for BRCA1 dysfunction was found in one of these tumours. We here describe the specific chromosomal aberrations in BRCA1-related breast carcinomas. We developed a predictive genetic test for BRCA1-association and show that BRCA1-related tumours can still be identified in HBOC families after routine DNA diagnostics.

2010-12-02 | GSE9021 | GEO

BRCA1 and BRCA2 classification of ovarian cancer

Project description:Inactivating germline BRCA1 and BRCA2 mutations confer a defect in homologous recombination DNA repair which was found to leave traces in tumor DNA copy number aberration (CNA) profiles. In analogy to previously trained breast cancer CNA classifiers that predicted association with BRCA1 and BRCA2 mutated cancer and benefit of high dose double strand break inducing chemotherapy, we trained BRCA1 and BRCA2 classifiers on CNA profiles of 50 BRCA1 mutated, 10 BRCA2 mutated and 13 non-familial ovarian cancers and investigated whether tumor type and mutation type independent classifiers could be trained. The cross validated area under the curve of the receiver/operator characteristic curve of ovarian cancer BRCA1 and BRCA2 classifiers were 0.67 (95% CI: 0.55-0.78) and 0.91 (95% CI: 0.79-1). These classifiers identified the majority of the samples with germline and somatic BRCA1 and BRCA2 mutations and BRCA1 promoter hypermethylation in the Cancer Genome Atlas (TCGA) dataset. Combining tumor type or mutated gene did not yield higher AUCs than single gene classifiers, although the ovarian BRCA1+BRCA2 classifier identified most BRCA1 and -2 mutated cases, including those in the TCGA dataset, and a combined breast and ovarian cancer BRCA1 classifier may improve response prediction to double strand break inducing chemotherapy.

2021-12-31 | GSE111688 | GEO

Distinct Brca1 mutations differentially reduce hematopoietic stem cell function

Project description:Mgbemena et al report that hematopoietic stem cells have an absolute requirement for Brca1 to survive. They also show that humanization of the mouse Brca1 e with a knocked-in BRCA1 cDNA, but not a mutant BRCA1/5382insC cDNA, fully substitutes for the mouse Brca1 during both embryonic development and hematopoiesis.

2017-02-01 | GSE91390 | GEO

RNAseq of Brca1-deficient mouse mammary tumors

Project description:Brca1 mutation predisposes women to early onset of breast and ovarian cancers.Through its diverse functions in DNA damage repair, cell cycle control, transcription regulation, ubiquitination and so on, BRCA1 acts as a very significant tumor suppressor and genomic safeguard. Brca1 deficiency induces severe cellular stress, when occurring in the mammary glands, it impairs the regular developmental process and eventually causes tumorigenesis due to accumulation of genome instability and other mechanisms. The Brca1-defiencient mouse mammary tumor were characterized with great tumoral heterogeneity, which is in line with the human breast cancers carrying BRCA1 mutations. Here we studied the molecular complexicity of Brca1-deficient mouse mammary tumors vie RNA sequencing.

2021-11-17 | GSE148565 | GEO

Understanding BRCA1 function in INK4-RB deficient tumors

Project description:Most BRCA1-deficient BLBCs carry a dysfunctional INK4-RB pathway. Thus, we have created genetically engineered mice with Brca1 loss and deletion of p16INK4A, or separately p18INK4C, to model the deficient INK4-RB signaling in human BLBC. By using these mutant mice and human BRCA1 deficient and proficient breast cancer tissues and cells, we tested if there exists a druggable target in BRCA1 deficient breast cancers.

2021-01-27 | GSE155239 | GEO

Non-breast/ovarian tumors in germline BRCA1/2 carriers

Project description:Non-breast/ovarian tumors in germline BRCA1/2 carriers

| PRJNA995882 | ENA

Non-breast/ovarian tumors in germline BRCA1/2 carriers

Project description:Non-breast/ovarian tumors in germline BRCA1/2 carriers

| PRJNA995883 | ENA